Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study

被引：0
|
作者：
Jin, Jie
Zhang, Yi
Zhang, Qike
Liu, Qingchi
Zhou, Hu
Gao, Sujun
Wang, Wei
Dang, Huibing
Chen, Yuqing
Wang, Jishi
Zhao, Peng
Yang, Haiping
Ma, Liangming
Zhao, Qingwei
Suo, Shanshan
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China
[3] Gansu Prov Hosp, Dept Hematol, Gansu, Peoples R China
[4] Hebei Med Univ, Dept Hematol, Hosp 1, Shijiazhuang, Peoples R China
[5] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[6] Jilin Univ, Dept Hematol, Affiliated Hosp 1, Changchun, Peoples R China
[7] Qingdao Univ, Affiliated Hosp, Dept Hematol, Med Coll, Qingdao, Peoples R China
[8] First Affiliated Hosp, Dept Hematol, Nanyang Med Coll, Nanyang, Peoples R China
[9] Henan Prov Peoples Hosp, Dept Hematol, Zhengzhou, Peoples R China
[10] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[11] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, Guiyang, Peoples R China
[12] Henan Univ Sci & Technol, Dept Hematol, Affiliated Hosp 1, Luoyang, Peoples R China
[13] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China
[14] Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Sch Med, Hangzhou, Peoples R China
[15] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7062
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study
    Zhang, Yi
    Zhou, Hu
    Xiao, Zhi-Jian
    Duan, Minghui
    Gao, Sujun
    He, Guangsheng
    Jing, Hongmei
    Li, Junmin
    Ma, Liangming
    Zhu, Huanling
    Chang, Chunkang
    Du, Xin
    Hong, Mei
    Li, Xin
    Liu, Qingchi
    Wang, Wei
    Xu, Na
    Yang, Haiping
    Zhao, Qingwei
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhang, Qike
    Liu, Qingchi
    Dang, Huibing
    Gao, Sujun
    Wang, Wei
    Zhou, Hu
    Chen, Yuqing
    Ma, Liangming
    Wang, Jishi
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Tong, Hongyan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1579 - 1587
  • [3] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
    Zhang, Yi
    Zhou, Hu
    Duan, Minghui
    Gao, Sujun
    He, Guangsheng
    Jing, Hongmei
    Li, Junmin
    Ma, Liangming
    Zhu, Huanling
    Chang, Chunkang
    Du, Xin
    Hong, Mei
    Li, Xin
    Liu, Qingchi
    Wang, Wei
    Xu, Na
    Yang, Haiping
    Lu, Binhua
    Yin, Hewen
    Wu, Liqing
    Suo, Shanshan
    Zhao, Qingwei
    Xiao, Zhijian
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, : 1588 - 1597
  • [4] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [5] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [6] Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update
    Martino, Bruno
    le Coutre, Philipp
    Griesshammer, Martin
    Illmer, Thomas
    Schlag, Rudolf
    Waller, Cornelius F.
    Liberati, Anna Marina
    Schafhausen, Philippe
    Tavares, Renato S.
    Vannucchi, Alessandro M.
    Giraldo, Pilar
    Foltz, Lynda M.
    Raanani, Pia
    Gupta, Vikas
    Tannir, Bayane
    Ronco, Julian Perez
    Ghosh, Jaggannath
    Al-Ali, Haifa Kathrin
    BLOOD, 2014, 124 (21)
  • [7] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
    O'Brien, Maureen M.
    Alonzo, Todd A.
    Cooper, Todd M.
    Levine, John E.
    Brown, Patrick A.
    Slone, Tamra
    August, Keith J.
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Patturajan, Meera
    Chen, Nianhang
    Simcock, Mathew
    Zimmerman, Linda
    Kolb, E. Anders
    PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
  • [8] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [9] SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE-1-RISK MYELOFIBROSIS (MF) FROM AN OPEN-LABEL, MULTICENTER, SINGLE-ARM EXPANDED-ACCESS STUDY
    Giraldo, P.
    Palandri, F.
    Palumbo, G. A.
    Zaritskey, A.
    Calistri, E.
    Skotnicki, A.
    Devos, T.
    Saavedra, D.
    Griesshammer, M.
    Al-Ali, H. K.
    Tavares, R.
    Vannucchi, A. M.
    Gupta, V.
    Raanani, P.
    Tannir, B.
    Ghosh, J.
    Ronco, J. Perez
    Foltz, L.
    HAEMATOLOGICA, 2015, 100 : 265 - 265
  • [10] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
12345